

**National Advisory Committee on Immunization (NACI) Summary of Discussion
February 6-7, 2013 Meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
Opening Remarks	The Chair, Dr. Bryna Warshawsky, welcomed participants to the meeting. New NACI member, Dr. Ian Gemmill was welcomed to the committee. New Liaison representative, Dr. Anne Pham-Huy from CAIRE was introduced and welcomed to NACI. She will be replacing Dr. Jason Brophy during his absence. New Ex-officio representatives, Dr. Carole Légaré from Marketed Biologicals, Biotechnology and Natural Health Products Bureau, Health Canada and Dr. Maureen Carew from First Nations and Inuit Health Branch, Health Canada were welcomed to NACI.
Canadian Immunization Guide (CIG) Planning	A status of the CIG revision was provided. Twenty-one of the Part 4 chapters are now web posted. Part 3 chapters are NACI approved and all Part 2 chapters are on the agenda for review during the meeting. Part 5 and 1 are the remaining chapters requiring NACI approval. An operational plan is being developed for the evergreen process. The management of ongoing updates and changes will be considered as part of the operational plan.
First review of CIG Chapter: Vaccine Administration Practices	This was NACI's first review of the Chapter. Members reviewed, discussed and resolved issues raised by the Working Group. The chapter will be revised to incorporate changes from this review and presented to NACI for 2 nd /final review at the March 25, 2013 teleconference.
First Review of CIG Chapter: Timing of Vaccine Administration	This was NACI's first review of the Chapter. Members reviewed, discussed and resolved issues raised by the Working Group. The chapter will be revised and presented to NACI for 2 nd /final review at the March 25, 2013 teleconference.
Second review of CIG Chapter: Vaccine Safety	This was NACI's second review of the Chapter. Issues which were previously raised by NACI and the Working Group have been resolved in consultation with the Biologics and Genetic Therapies Directorate (BGTD). The purpose of this review was to address new issues. Following today's review the chapter will be further reviewed by the designated Working Group and NACI reviewers and then sent to the Working Group and NACI Chair for approval.
Second review of CIG Chapter: Contraindications and Precautions	This was NACI's second review of the chapter. The purpose of the chapter is to orient the end user so they are able to find the information they need on contraindications and precautions. Following today's review the chapter will be further reviewed by the designated Working Group and NACI reviewers and then sent to the Working Group and NACI Chair for approval.

**National Advisory Committee on Immunization (NACI) Summary of Discussion
February 6-7, 2013 Meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
Second review of CIG Chapter: Early Vaccine Reactions including Anaphylaxis	This was NACI's second review of the chapter. Following incorporation of the changes suggested today, the chapter will be further reviewed by the designated Working Group and NACI reviewers and then sent to the Working Group and NACI Chair for approval.
Second review of CIG Chapter: Anaphylaxis hypersensitivity to egg chapter	This was NACI's second review of the chapter. Following incorporation of the changes suggested today, the chapter will be further reviewed by the designated Working Group and NACI reviewers and then sent to the Working Group and NACI Chair for approval.
Second review of CIG Chapter: Smallpox	This was NACI's second review of the chapter. Following incorporation of the changes suggested today, the chapter will be sent to the Working Group and NACI Chair for final approval.
First review of CIG Chapter: Tick-Borne Encephalitis	This was NACI's first review of the chapter. Members from the Committee to Advise on Tropical Medicine and Travel (CATMAT) participated in the agenda item via teleconference. The chapter will be revised and sent for second review and approval by email.
Vaccine Safety Working Group (VS WG)	The purpose of this item was to review and obtain comments on the working group's draft Terms of Reference (ToR). The draft ToR are to be updated as per NACI's feedback, and following these reviews and revisions, the document will be sent to the NACI-VSWG and the NACI Chair for further comments and approval.
Liaison Representative and Ex-officio Updates	Updates were provided by liaison representatives and ex-officio members including the: Association of Medical Microbiology and Infectious Disease Canada (AMMI), Canadian Association for Immunization Research and Evaluation (CAIRE), Canadian Immunization Committee (CIC), College of Family Physicians of Canada (CFPC), First Nations and Inuit Health Branch (FNIHB), Canadian Public Health Association (CPHA), Council of Chief Medical Officers of Health (CCMOH), Canadian Paediatrics Society (CPS), Centers for Disease Control and Prevention (CDC), College of Family Physicians of Canada, Biologics and Genetic Therapies Directorate (BGTD - Health Canada), First Nations and Inuit Health Branch (Health Canada), Marketed Biological, Biotechnology and Natural Health Products Bureau (Health Canada), Pandemic Preparedness Division, Centre for Immunization and Respiratory Infectious Diseases (PHAC), Vaccine Preventable Diseases, Centre for Immunization and Respiratory Infectious Diseases (PHAC).

**National Advisory Committee on Immunization (NACI) Summary of Discussion
February 6-7, 2013 Meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
NACI Statement: 2013-14 Seasonal Influenza Vaccine Interim Statement Swine and Poultry Workers	<p>The Influenza Working Group (IWG) Chair provided additional background information on influenza vaccination and swine and poultry workers since the October 2012 NACI meeting in addition to options for inclusion of specific recommendations in the 2013-2014 statement.</p> <p>The Chair presented the 2013-2014 interim seasonal influenza statement. The timing of the influenza interim and full statements was discussed. The 2013-14 Interim statement will be adjusted as per the decisions made and a revised draft will be sent to NACI for final approval. The Working Group Chair presented the IWG ToR, which were recently revised based on the approved NACI ToR, for approval. The IWG ToR was approved and NACI members were advised to send any additional comments to the IWG chair following the meeting.</p>
NACI Statement: Pertussis / Polio / Addressing the Quadracel® Shortage	<p>The focus of this agenda item was to update NACI on the progress of the statement update and to obtain general feedback on the current draft. The final statement, which will include the recommendations, is expected to be ready for NACI review and approval in March. The focus of the work group, as per the request from CCMOH, is on the pertussis and polio vaccine components and not specifically diphtheria or tetanus.</p>
Pertussis - Potential approach to more timely NACI products	<p>At the October 2013 meeting, NACI requested that the Pertussis Working Group consider the issues of vaccination in pregnancy, recommendations for and effectiveness of cocooning strategies and waning immunity in adolescents and adults. The priority issue for the working group is to review vaccination in pregnancy as this is the higher priority at this time. The working group will aim to have the first draft of the statement ready for the June meeting.</p>
NACI Terms of Reference (TOR)	<p>The Associate Director General informed the Committee that the updated NACI ToR has been approved by the Assistant Deputy Minister, Infectious Disease Prevention and Control Branch. Following the meeting, the selection process for the Vice-Chair will be initiated. As per the approved NACI ToR, the Vice-Chair will be appointed for a 2 years term with the potential for a one year extension.</p>
General NACI Business	<p>The Status Report on NACI Work Plan Activities was provided to members for their information.</p>

**National Advisory Committee on Immunization (NACI) Summary of Discussion
February 6-7, 2013 Meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
Update on Meningococcal B Pilot Project	A status update on the Meningococcal B pilot project was provided. The updated literature review and the draft NACI statement and recommendations were presented to NACI. NACI members are to review and provide additional comments on the literature review and the draft statement following the meeting.
NACI Statement: Update on Herpes Zoster	The focus of this agenda item was to provide an update on work to date and to present a draft of the herpes zoster statement update for review and comment. The statement will be sent to NACI for a second review and approval via email following the meeting.
National Immunization Strategy (NIS)	The Associate Director General, Centre for Immunization and Respiratory Infectious Diseases provided an update on the Public Health Network review of the NIS.
Adjournment	The NACI Chair thanked members for their contributions and adjourned the meeting.